"Thanks to [the Movement Disorders Foundation], we're uncovering molecular pathways and mechanisms at the core of the Parkinson's disease pathology itself.... By setting the ground to test drugs that are already FDA approved, we're ahead of the curve to prove that these drugs [can] work to slow down the progression of Parkinson's disease."

Daniel Paredes, Ph. D. is a Research Assistant Professor at the Knoebel Institute for Healthy Aging at the University of Denver and the first recipient of a Movement Disorders Foundation Pilot Grant.